Cargando…
Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study
BACKGROUND: After new analysis, Sanofi Pasteur now recommends their dengue vaccine (Dengvaxia) should only be given to individuals previously infected with dengue and the World Health Organization’s recommendations regarding its use are currently being revised. As a result, the potential costs of pe...
Autores principales: | Turner, Hugo C, Wills, Bridget A, Rahman, Motiur, Quoc Cuong, Hoang, Thwaites, Guy E, Boni, Maciej F, Clapham, Hannah E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092611/ https://www.ncbi.nlm.nih.gov/pubmed/29982700 http://dx.doi.org/10.1093/trstmh/try057 |
Ejemplares similares
-
The Estimates of the Health and Economic Burden of Dengue in Vietnam
por: Hung, Trinh Manh, et al.
Publicado: (2018) -
A review of Dengvaxia®: development to deployment
por: Thomas, Stephen J., et al.
Publicado: (2019) -
Dengvaxia controversy: impact on vaccine hesitancy
por: Fatima, Khunsha, et al.
Publicado: (2018) -
Dengvaxia: the world’s first vaccine for prevention of secondary dengue
por: Tully, Danielle, et al.
Publicado: (2021) -
Affordability of antimicrobials for animals and humans in Vietnam: A call to revise pricing policies
por: Carrique-Mas, Juan, et al.
Publicado: (2019)